Neuroscience

One particularly important area where we are placing our Partnering efforts is in Neuroscience. We believe the field of Neuroscience is on the cusp of important breakthroughs in both early diagnosis and treatment. Our relentless pursuit of scientific innovation is taking us into areas of enormous unmet medical need and progress in treating diseases of the brain and nervous system.

Our collaborative efforts have resulted in one of the strongest and most diverse pipelines in the industry, spanning the spectrum of nervous system disorders from the rarest to the most common.

Partnering opportunities we are looking for:

• Neurodegenerative diseases (e.g. Alzheimer's disease, Parkinson's disease, Huntington disease)
• Neuroimmunology and neuroinflammation (e.g. Multiple sclerosis)
• Neurodevelopment and psychiatry (e.g. Angelman Syndrome, Schizophrenia, and Autism spectrum disorders)
• Neuromuscular diseases (e.g. SMA and Duchenne Muscular Dystrophy)

Example partnerships

Atalanta – Multi-target SiRNA drug discovery collaboration.

UCB – Development and commercialization of antibody treatment for people living with Alzheimer’s Disease.

Your dedicated partnering leads in Neuroscience

Tom Zioncheck, Head of Neuroscience, Ophthalmology and Rare Diseases, Pharma Partnering

Hannah Williams, Search & Evaluation Lead Neuroscience, Ophthalmology & Rare Diseases, Pharma Partnering